A new Mounjaro lawsuit does not come from a patient. It comes from inside Eli Lilly’s own sales force.
On November 9, 2026, former Lilly senior territory manager Jennifer Mansion filed a complaint in federal court in Dallas, alleging that the company fired her after she objected to colleagues promoting Mounjaro as a weight-loss treatment before tirzepatide had received FDA approval for that use.
The allegations concern events in 2023, when Mounjaro was approved for type 2 diabetes but the same active ingredient had not yet been authorized for chronic weight management.
Mansion says she warned supervisors and human resources personnel about the conduct, questioned a physician’s presentation at a Lilly-sponsored luncheon, and faced retaliation for repeatedly raising the issue.
Her employment ended on November 9, 2023. That was one day after the FDA approved Zepbound, Lilly’s weight-management brand of tirzepatide.
The timing is striking, but timing alone does not establish why she was fired.
Lilly denies wrongdoing and maintains that the claim should be dismissed, according to reporting by STAT. The allegations have not been established in court.
This is also not Mansion’s first attempt to pursue the case. Her earlier lawsuit in New Jersey was dismissed in August 2026 because the court lacked personal jurisdiction over Lilly, not because a judge decided whether her accusations were true.
The new Texas case gives the dispute another opportunity to be heard.
Compared with the thousands of product-liability claims involving GLP-1 medicines, Mansion’s employment lawsuit is relatively narrow. But it raises a different question about the industry’s most profitable drugs: what happens when an employee challenges how a medicine is being sold before its regulatory label catches up with public demand?
This case is about alleged marketing conduct and retaliation, not whether Mounjaro works for weight loss.
What the Mounjaro Lawsuit Actually Alleges
The complaint is filed as Mansion v. Eli Lilly & Co., case number 3:26-cv-03924, in the United States District Court for the Northern District of Texas.
It asserts three claims: retaliation under the federal False Claims Act, retaliation under the Texas Medicaid Fraud Prevention Act, and retaliation in violation of Texas public policy.
According to the filing, Mansion joined Lilly’s Dallas Diabetes Business Unit on October 3, 2022, as a senior territory manager responsible for the Plano, Texas, territory.
Her responsibilities included presenting Mounjaro, Trulicity and Jardiance to medical practices.
She alleges that she performed well, received favorable evaluations and had not been formally disciplined before her dismissal.
Her central accusation is that other Lilly sales representatives were encouraging healthcare providers to prescribe Mounjaro for obesity even though its FDA-approved indication at the time concerned type 2 diabetes.
Mansion says she observed this conduct during her sales work and raised concerns that the company’s diabetes representatives should promote the drug within its approved indication.
One particularly specific allegation concerns a Lilly-sponsored lunch program at Baylor Scott & White Primary Care in Rockwall, Texas, on May 4, 2023.
The complaint says a physician presenting at that event promoted Mounjaro for an unapproved use. Mansion alleges that she subsequently contacted a Lilly human resources employee by email about her concerns.
She also alleges that a supervisor discouraged her from avoiding the weight-loss indication because Lilly expected to obtain that approval soon.
These are descriptions from the plaintiff’s complaint, not independent findings about what was said at the meeting or what Lilly authorized.
Bloomberg Law reports that Mansion also accuses Lilly of causing Texas Medicaid to pay millions of dollars in improper reimbursements.
That allegation is central to her attempt to bring the dispute under laws protecting employees who object to suspected fraud involving government healthcare programs.
The complaint alleges an improper sales campaign, a series of internal objections and a retaliatory firing. It does not, by itself, prove any of them.
The 18-Month Gap Between Mounjaro and Zepbound
The timeline explains why these allegations matter.
On May 13, 2022, the FDA approved Mounjaro, a once-weekly injection containing tirzepatide, to improve blood glucose control in adults with type 2 diabetes, alongside diet and exercise.
Tirzepatide activates two hormone receptors, GIP and GLP-1, which influence glucose regulation, appetite and other metabolic processes.
Weight reduction was already an important finding from tirzepatide’s clinical development program, and Lilly was studying the molecule for obesity treatment.
But evidence that a drug reduces weight is not the same thing as FDA authorization to market it for chronic weight management.
That authorization arrived on November 8, 2023, when the FDA approved Zepbound for eligible adults with obesity or overweight and a qualifying weight-related condition.
Zepbound and Mounjaro contain the same active ingredient, tirzepatide, but they were approved under different brand names and indications.
Between the Mounjaro approval in May 2022 and the Zepbound approval in November 2023, there was a period of approximately eighteen months during which tirzepatide was commercially available in the United States without an approved weight-management indication.
Physicians could legally prescribe Mounjaro for uses outside its approved label when exercising their medical judgment. That practice is generally called off-label prescribing.
Manufacturer promotion is a different legal question.
FDA rules restrict marketing that presents an approved prescription medicine as intended for an unapproved use. The agency also recognizes distinctions involving truthful, non-misleading scientific information communicated to healthcare professionals outside ordinary promotional activity.
Those distinctions matter here. A doctor choosing to prescribe Mounjaro for weight loss was not automatically violating federal law. Nor would every scientific discussion of tirzepatide’s weight-loss data necessarily amount to unlawful promotion.
The disputed question is whether Lilly personnel were conducting improper promotional activity and whether Mansion reasonably believed that activity could produce fraudulent claims against government healthcare programs.
Doctors may prescribe off-label. Whether a manufacturer improperly promoted an unapproved use depends on what was communicated, by whom, and in what context.
From a March Warning to a November Firing
The newly filed complaint provides a more detailed chronology than the initial news summaries.
Mansion alleges that she first raised her concerns with her supervisor during a field visit on March 21, 2023.
She says she was worried about how frequently healthcare providers were prescribing Mounjaro for obesity rather than type 2 diabetes and about how other representatives were discussing the medicine.
The May 4 luncheon became another point of dispute.
According to the complaint, Mansion again questioned the off-label promotion of Mounjaro and told her supervisor that Lilly should focus its sales activities on the drug’s approved indication.
She alleges that she contacted human resources about the luncheon and the company’s approach to promoting the medicine.
On June 23, 2023, Mansion says she had another conversation with human resources about her objections.
Her filing then describes deteriorating relations at work, disputes involving time off, and what she regarded as increasingly unfair treatment.
In August, she says she again raised the off-label issue with human resources and sought a transfer to a different team.
She alleges that her requests were denied and that her efforts to secure another position within Lilly were obstructed.
Further complaints followed in September and October, according to the filing.
On November 8, 2023, Mansion says she met with a senior human resources official to discuss what she considered retaliation and unfair treatment.
The following morning, she says she spoke with Lilly’s chief compliance officer about workplace concerns related to the alleged retaliation.
Lilly terminated her employment on November 9, 2023, according to the complaint.
The sequence is relevant to a retaliation claim because employees generally must show that their employer knew about protected activity and that the activity caused an adverse employment action.
Repeated complaints and a dismissal close in time can help establish a factual chronology. They do not independently establish that the employer’s stated or actual reason for terminating employment was unlawful.
That question will require examination of the communications, performance records, decision-making process and Lilly’s explanation.
For now, readers have one side’s account in a filed complaint.
The court has not determined whether Mansion’s objections were legally protected activity or whether those objections caused her dismissal.
Why Texas Is Jennifer Mansion’s Second Court
Mansion originally filed her lawsuit in the United States District Court for the District of New Jersey on November 7, 2025.
Lilly sought dismissal, arguing in part that the New Jersey court lacked personal jurisdiction over the company for the claims at issue.
On August 28, 2026, the New Jersey court dismissed the case without prejudice for lack of personal jurisdiction, according to Law360 and the federal docket.
A dismissal for lack of personal jurisdiction is not a finding that the defendant did nothing wrong. It means the court cannot properly exercise authority over the defendant in that dispute.
That distinction is essential.
The New Jersey court did not hold a trial and decide whether Lilly representatives improperly promoted Mounjaro or whether Mansion suffered retaliation.
The dismissal without prejudice left open the possibility of pursuing the claims in another appropriate forum.
Mansion chose Texas, where she had worked for Lilly, where much of the alleged conduct occurred, and where her complaint says the disputed Medicaid reimbursements arose.
The November 9, 2026, complaint was filed in the Northern District of Texas, Dallas Division, before Judge David C. Godbey.
As of November 12, the publicly accessible Texas docket reviewed for this article showed the newly filed complaint, but not a substantive ruling on its allegations.
The new filing therefore removes the immediate question of why a New Jersey court should hear a Texas employment dispute. It does not automatically resolve every legal challenge Lilly may raise.
Questions about the sufficiency of the allegations, the applicable statutes, timing, causation and available remedies may still arise.
New Jersey decided it was not the right court. Texas has not yet decided who was right.
Why the Texas Medicaid Allegation Matters
Mansion’s complaint reaches beyond the question of whether an employee was treated unfairly.
It alleges that improper promotion of Mounjaro led to the submission of claims for Medicaid reimbursement that should not have been paid.
The filing states that Texas Medicaid disbursed millions of dollars in reimbursements allegedly connected to Lilly’s unlawful marketing activities.
That is an allegation, not a verified accounting of improper payments.
The federal False Claims Act addresses fraud involving government funds and includes protections for employees who engage in lawful activity to stop suspected violations.
Its retaliation provision, 31 U.S.C. Section 3730(h), can apply when an employee is discharged, demoted, harassed or otherwise discriminated against because of qualifying protected conduct.
Mansion also invokes a retaliation provision of the Texas Medicaid Fraud Prevention Act.
The central issue for those claims is whether Mansion engaged in protected activity under the relevant laws and whether Lilly retaliated against her because of it.
That is distinct from proving every alleged improper Medicaid payment or establishing liability for a broader reimbursement scheme.
Off-label prescribing, by itself, does not prove that a prescription was fraudulent.
To establish that claims were improper, the evidence would need to address the applicable coverage and reimbursement rules, the prescriptions and claims actually submitted, any material misrepresentations, and the connection between the alleged promotional conduct and those claims.
The complaint does not publicly establish a verified list of false claims or a final accounting of the alleged losses.
There is a related development that requires careful separation.
In August 2025, the Texas attorney general filed a separate lawsuit accusing Lilly of improperly inducing healthcare providers to prescribe its medicines, including Mounjaro and Zepbound, through allegedly unlawful incentives and reimbursement-support arrangements.
Mansion’s new complaint references that litigation.
But the attorney general’s case concerns a different set of allegations and is not a court finding that Mansion’s account is correct.
Nor does the existence of that lawsuit demonstrate that any particular Mounjaro prescription described by Mansion was improperly reimbursed.
The government’s financial exposure is what gives the alleged marketing conduct added legal significance. Whether that exposure resulted from unlawful conduct remains disputed.
What the Lawsuit Means for Lilly’s GLP-1 Business
Lilly’s tirzepatide business has become one of the most commercially important pharmaceutical franchises in the world.
Mounjaro established the product in diabetes treatment, while Zepbound extended tirzepatide into the approved weight-management market.
As Grey Pepper examined in its coverage of Lilly’s third-quarter 2026 Mounjaro and Zepbound sales, growth in the franchise has made obesity and metabolic medicine central to the company’s financial performance.
That scale makes allegations about marketing practices consequential even when they arise from an individual employment dispute.
Pharmaceutical companies routinely face scrutiny over the distinction between communicating scientific evidence and promoting medicines for indications that regulators have not approved.
For a drug with widely discussed weight-loss effects before its obesity approval, that distinction was particularly relevant.
But the existence of intense public demand does not establish that a manufacturer authorized improper promotion, and the fact that tirzepatide later received weight-management approval does not determine the legality of earlier marketing conduct.
Mansion’s allegations also differ fundamentally from the product-liability lawsuits confronting GLP-1 manufacturers.
Those cases generally concern alleged adverse reactions, product warnings and questions of causation.
Grey Pepper has separately covered the expanding litigation over GLP-1 medicines and vision-loss allegations.
Mansion is not alleging that she was physically injured by tirzepatide.
She alleges that she lost her job after refusing to participate in, or remain silent about, marketing behavior she believed was unlawful.
That makes the evidentiary questions different.
Instead of clinical trial data or adverse-event histories, the case may turn on workplace correspondence, training materials, supervisory instructions, human resources records and the circumstances of the termination.
Lilly’s position must be considered alongside the allegations. The company denies wrongdoing, according to STAT’s November 10 reporting.
At the time of this article’s review, the available Texas docket did not establish that the court had decided any substantive dispute or that discovery had produced independent verification of the plaintiff’s account.
For investors and industry observers, this is a reason to follow the litigation, not to assume a regulatory violation has occurred.
This lawsuit is about how a drug was allegedly sold and how an employee was allegedly treated, not about whether the drug was effective.
What Happens Next in the Mounjaro Lawsuit?
The immediate question is whether Mansion’s Texas complaint can survive the legal challenges Lilly may bring.
Her claims require more than demonstrating that healthcare providers discussed Mounjaro’s weight-loss effects while its approved indication concerned diabetes.
She will need to establish the elements of the relevant retaliation claims, including qualifying protected conduct and a connection between that conduct and her dismissal.
The court may also have to examine whether her allegations about suspected Medicaid fraud were sufficiently connected to activity protected by the statutes she invokes.
If the case proceeds to discovery, the parties could seek records about how Mounjaro was presented to healthcare professionals during 2023 and how Lilly handled Mansion’s internal objections.
Potentially relevant materials could include field-visit reports, speaker-program records, communications between sales representatives and supervisors, and internal human resources correspondence.
Whether those records exist, are discoverable, and support either side’s position remains to be seen.
There is no basis at this stage to conclude that Lilly carried out a companywide off-label sales campaign, deliberately caused false Medicaid claims, or fired Mansion because of protected whistleblowing activity.
The opposite conclusion, that her allegations are unfounded, has not been established either.
What is established is the chronology.
Mounjaro received its diabetes approval in May 2022. Mansion says she began objecting to weight-loss promotion in March 2023. Zepbound received FDA approval for weight management on November 8, 2023. Mansion’s employment ended the following day.
She filed in New Jersey in 2025, lost that venue on jurisdictional grounds in August 2026, and brought the allegations to a Texas federal court on November 9, 2026.
It is a specific factual sequence, now part of a public legal record.
The unresolved question is what that sequence means.
For a pharmaceutical company built around carefully regulated medical products, the boundary between an approved indication and a commercial sales message is more than a technicality.
For an employee who says she raised concerns about that boundary, proving retaliation is a separate and demanding legal task.
Texas is now the court where those questions may be tested.
The filing is a serious allegation, not a verdict. The next meaningful development will be evidence, not another accusation.
Sources and Further Reading
- U.S. District Court, Northern District of Texas — Mansion v. Eli Lilly & Co., Complaint, Document 1, filed November 9, 2026. Primary court filing, 25 pages.
- Justia — Mansion v. Eli Lilly & Co., Texas federal docket, case 3:26-cv-03924.
- STAT — Ed Silverman, Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug, November 10, 2026.
- Bloomberg Law — Eli Lilly Hit With Retaliation Suit Concerning Mounjaro Sales, November 9, 2026.
- Law360 — Ex-Eli Lilly Rep Fights Firing After Flagging Mounjaro Abuse, November 9, 2026.
- Law360 — Ex-Eli Lilly Rep Can’t File Whistleblower Claims In NJ, August 28, 2026.
- Justia — Mansion v. Eli Lilly & Co., New Jersey federal docket, case 3:25-cv-17282, filed November 7, 2025.
- U.S. Food and Drug Administration — Mounjaro (tirzepatide), original approval May 13, 2022.
- U.S. Food and Drug Administration — FDA Approves New Medication for Chronic Weight Management, Zepbound, November 8, 2023.
- U.S. Food and Drug Administration — Scientific Information on Unapproved Uses of Approved Medical Products, January 2025 guidance, marked not for current implementation.
- Office of the Texas Attorney General — Separate lawsuit alleging improper prescription inducements involving Eli Lilly, August 12, 2025.
